Theravance Biopharma Inc $ 17.96 -2.88 (-13.82%)
Volume:
737,105
Avg Vol (1m):
501,347
Market Cap $:
1.13 Bil
Enterprise Value $:
1.30 Bil
P/E (TTM):
0.00
P/B:
0.00
Financial Strength | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.74 | ||
| Equity-to-Asset | -0.26 | ||
| Debt-to-Equity | -4.15 | ||
| Debt-to-EBITDA | -3.1 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | -2.37 | ||
| Beneish M-Score | -0.91 | ||
| WACC vs ROIC | |||
Profitability Rank | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -285.12 | ||
| Net Margin % | -280.8 | ||
| ROA % | -49.72 | ||
| ROC (Joel Greenblatt) % | -363.01 | ||
| 3-Year Revenue Growth Rate | 6.7 | ||
| 3-Year EBITDA Growth Rate | 2.4 | ||
| 3-Year EPS without NRI Growth Rate | 0.1 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PS Ratio | 11.56 | ||
| EV-to-EBIT | -5.97 | ||
| EV-to-EBITDA | -6.16 | ||
| EV-to-Revenue | 14.8 | ||
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.45 | ||
| Days Sales Outstanding | 63.98 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Earnings Yield (Greenblatt) % | -16.75 |